¡Ya estamos en !
Descubre más
LJPC
La Jolla Pharmaceutical Company
Excluida de cotización
LJPC dejó de cotizar en bolsa el 19 de agosto de 2022.
Acerca de: La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Empleados: 66
Noticias
Positivo
Neutral
Negativo
Sentimiento
3 meses
Positivo
0%
Neutral
0%
Negativo
0%
No hemos recibido artículos de noticias recientes sobre LJPC.
Gráficos de precios implementados con Lightweight Charts™